---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-006352"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:45:48.906846+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail

## Summary
- Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).
- Auditor JP Centurion & Partners reappointed with 10,720,634 votes for.
- 2024 Stock Incentive Plan not approved: 4,094,117 for, 6,382,176 against.
- Reverse stock split (1:2 to 1:10) not approved: 4,371,573 for, 6,378,201 against.
- Company alleges former officer/director directed unlawful proxy solicitation affecting Proposals 3&4; board authorized investigation, may pursue litigation.

## SEC filing metadata
- accession: 0001477932-24-006352
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793224006352/0001477932-24-006352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793224006352/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-006352
- JSON: https://secwatch.observer/filing/0001477932-24-006352.json
- Plain text: https://secwatch.observer/filing/0001477932-24-006352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.